BioCentury
ARTICLE | Company News

Maxygen, Astellas deal

September 22, 2008 7:00 AM UTC

The partners will co-develop preclinical candidates in Maxygen's MAXY-4 program of second-generation CTLA4-Ig fusion proteins to treat rheumatoid arthritis (RA) and other autoimmune diseases, and Astellas received exclusive, worldwide rights to develop and market the candidates to treat transplant rejection. Maxygen will receive $10 million up front and is eligible for up to $160 million in milestones, plus tiered, double-digit royalties. In North America, Maxygen has an option to co-promote autoimmune products and share in profits. ...